Emergent Biosolutions Inc

NYSE:EBS  
63.51
-1.97 (-3.01%)
Products

Emergent Biosolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating Chikv Vlp

Published: 05/26/2021 10:47 GMT
Emergent Biosolutions Inc (EBS) - Emergent Biosolutions Announces Positive Two-year Persistence Data From Phase 2 Study Evaluating Chikv Vlp, the Company’s Chikungunya Virus Virus-like Particle Vaccine Candidate.
Emergent - Dose-related Increase in Immune Response, As Measured by Anti-chikungunya Virus Serum Neutralizing Antibodies, Was Previously Observed.
Emergent Biosolutions - Chikungunya Virus Virus-like Particle Vaccine Candidate Was Well-tolerated.
Emergent - Majority of Solicited Adverse Events Were Mild Or Moderate in Severity & Most Frequent Was Local Injection Site Pain.